United Services Automobile Association lowered its stake in USANA Health Sciences, Inc. (NYSE:USNA) by 8.1% during the second quarter, HoldingsChannel reports. The institutional investor owned 9,810 shares of the company’s stock after selling 859 shares during the quarter. United Services Automobile Association’s holdings in USANA Health Sciences were worth $779,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Nuveen Asset Management LLC acquired a new position in USANA Health Sciences in the second quarter valued at about $17,458,000. UBS Asset Management Americas Inc. lifted its position in USANA Health Sciences by 19.9% in the second quarter. UBS Asset Management Americas Inc. now owns 9,172 shares of the company’s stock valued at $729,000 after buying an additional 1,521 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its position in USANA Health Sciences by 13.1% in the second quarter. D. E. Shaw & Co. Inc. now owns 271,443 shares of the company’s stock valued at $21,560,000 after buying an additional 31,396 shares during the last quarter. Morgan Stanley lifted its position in USANA Health Sciences by 0.3% in the second quarter. Morgan Stanley now owns 297,254 shares of the company’s stock valued at $23,611,000 after buying an additional 773 shares during the last quarter. Finally, Invesco Ltd. lifted its position in USANA Health Sciences by 208.9% in the second quarter. Invesco Ltd. now owns 52,408 shares of the company’s stock valued at $4,163,000 after buying an additional 35,443 shares during the last quarter. 63.40% of the stock is currently owned by institutional investors.
Several analysts have recently issued reports on USNA shares. Pivotal Research reissued a “buy” rating on shares of USANA Health Sciences in a research report on Wednesday, July 24th. TheStreet cut shares of USANA Health Sciences from a “b-” rating to a “c+” rating in a research report on Thursday, July 11th. ValuEngine raised shares of USANA Health Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Sidoti cut shares of USANA Health Sciences from a “buy” rating to a “neutral” rating and set a $70.00 price target on the stock. in a research report on Wednesday, July 3rd. Finally, Jefferies Financial Group started coverage on shares of USANA Health Sciences in a research report on Thursday, August 22nd. They set a “hold” rating and a $65.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. USANA Health Sciences presently has a consensus rating of “Hold” and an average target price of $70.00.
In other news, Director Robert Auciaux sold 4,018 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $71.87, for a total transaction of $288,773.66. The sale was disclosed in a legal filing with the SEC, which is available at this link. 42.50% of the stock is currently owned by corporate insiders.
Shares of USNA opened at $68.40 on Friday. The stock has a market capitalization of $1.50 billion, a PE ratio of 15.03 and a beta of 0.39. USANA Health Sciences, Inc. has a 1 year low of $58.30 and a 1 year high of $125.61. The company’s 50-day simple moving average is $68.75 and its 200-day simple moving average is $73.13.
USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, July 23rd. The company reported $0.91 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.93 by ($0.02). The business had revenue of $256.00 million for the quarter, compared to analyst estimates of $254.66 million. USANA Health Sciences had a return on equity of 27.22% and a net margin of 9.68%. The firm’s revenue for the quarter was down 15.1% compared to the same quarter last year. During the same period in the prior year, the company posted $1.36 EPS. On average, equities research analysts forecast that USANA Health Sciences, Inc. will post 3.78 EPS for the current year.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
Recommended Story: Average Daily Trade Volume Explained
Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNA).
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.